Microbicides for the prevention of sexually transmitted HIV infection.
Identifieur interne : 002567 ( Main/Exploration ); précédent : 002566; suivant : 002568Microbicides for the prevention of sexually transmitted HIV infection.
Auteurs : Quarraisha Abdool Karim [Afrique du Sud] ; Cheryl BaxterSource :
- Expert review of anti-infective therapy [ 1744-8336 ] ; 2013.
Descripteurs français
- KwdFr :
- Administration par voie rectale, Administration par voie vaginale, Animaux, Anti-infectieux (administration et posologie), Anti-infectieux (métabolisme), Essais cliniques comme sujet (tendances), Femelle, Humains, Infections à VIH (), Infections à VIH (métabolisme), Infections à VIH (transmission), Maladies sexuellement transmissibles (), Maladies sexuellement transmissibles (métabolisme), Maladies sexuellement transmissibles (transmission), Mâle.
- MESH :
- administration et posologie : Anti-infectieux.
- métabolisme : Anti-infectieux, Infections à VIH, Maladies sexuellement transmissibles.
- tendances : Essais cliniques comme sujet.
- Administration par voie rectale, Administration par voie vaginale, Animaux, Femelle, Humains, Infections à VIH, Maladies sexuellement transmissibles, Mâle.
English descriptors
- KwdEn :
- Administration, Intravaginal, Administration, Rectal, Animals, Anti-Infective Agents (administration & dosage), Anti-Infective Agents (metabolism), Clinical Trials as Topic (trends), Female, HIV Infections (metabolism), HIV Infections (prevention & control), HIV Infections (transmission), Humans, Male, Sexually Transmitted Diseases (metabolism), Sexually Transmitted Diseases (prevention & control), Sexually Transmitted Diseases (transmission).
- MESH :
- chemical , administration & dosage : Anti-Infective Agents.
- chemical , metabolism : Anti-Infective Agents.
- metabolism : HIV Infections, Sexually Transmitted Diseases.
- prevention & control : HIV Infections, Sexually Transmitted Diseases.
- transmission : HIV Infections, Sexually Transmitted Diseases.
- trends : Clinical Trials as Topic.
- Administration, Intravaginal, Administration, Rectal, Animals, Female, Humans, Male.
Abstract
The impetus for, and efforts in the past 20 years toward a women-initiated method for preventing sexual transmission of HIV has been previously well described. To date, four classes of topical agents categorized by mechanism of action as: surfactants, buffers, cell entry blockers and antiretroviral agents have undergone advanced clinical testing. Thus far, only coitally linked use of 1% tenofovir gel has demonstrated moderate effectiveness in preventing HIV and HSV-2 infection and has generated renewed hope for microbicide development. Studies of new antiviral agents, novel delivery mechanisms and combination/multipurpose products that address challenges of adherence and enhance the effectiveness of tenofovir gel are already underway to further enhance sexual and reproductive health needs of men and women and efforts to prevent HIV infection.
DOI: 10.1586/eri.12.153
PubMed: 23428099
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001672
- to stream PubMed, to step Curation: 001672
- to stream PubMed, to step Checkpoint: 001672
- to stream Ncbi, to step Merge: 001C88
- to stream Ncbi, to step Curation: 001C88
- to stream Ncbi, to step Checkpoint: 001C88
- to stream Main, to step Merge: 002574
- to stream Main, to step Curation: 002567
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Microbicides for the prevention of sexually transmitted HIV infection.</title><author><name sortKey="Karim, Quarraisha Abdool" sort="Karim, Quarraisha Abdool" uniqKey="Karim Q" first="Quarraisha Abdool" last="Karim">Quarraisha Abdool Karim</name><affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, South Africa. abdoolq2@ukzn.ac.za</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal</wicri:regionArea><wicri:noRegion>University of KwaZulu-Natal</wicri:noRegion></affiliation></author><author><name sortKey="Baxter, Cheryl" sort="Baxter, Cheryl" uniqKey="Baxter C" first="Cheryl" last="Baxter">Cheryl Baxter</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23428099</idno><idno type="pmid">23428099</idno><idno type="doi">10.1586/eri.12.153</idno><idno type="wicri:Area/PubMed/Corpus">001672</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001672</idno><idno type="wicri:Area/PubMed/Curation">001672</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001672</idno><idno type="wicri:Area/PubMed/Checkpoint">001672</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001672</idno><idno type="wicri:Area/Ncbi/Merge">001C88</idno><idno type="wicri:Area/Ncbi/Curation">001C88</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C88</idno><idno type="wicri:Area/Main/Merge">002574</idno><idno type="wicri:Area/Main/Curation">002567</idno><idno type="wicri:Area/Main/Exploration">002567</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Microbicides for the prevention of sexually transmitted HIV infection.</title><author><name sortKey="Karim, Quarraisha Abdool" sort="Karim, Quarraisha Abdool" uniqKey="Karim Q" first="Quarraisha Abdool" last="Karim">Quarraisha Abdool Karim</name><affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, South Africa. abdoolq2@ukzn.ac.za</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal</wicri:regionArea><wicri:noRegion>University of KwaZulu-Natal</wicri:noRegion></affiliation></author><author><name sortKey="Baxter, Cheryl" sort="Baxter, Cheryl" uniqKey="Baxter C" first="Cheryl" last="Baxter">Cheryl Baxter</name></author></analytic><series><title level="j">Expert review of anti-infective therapy</title><idno type="eISSN">1744-8336</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intravaginal</term><term>Administration, Rectal</term><term>Animals</term><term>Anti-Infective Agents (administration & dosage)</term><term>Anti-Infective Agents (metabolism)</term><term>Clinical Trials as Topic (trends)</term><term>Female</term><term>HIV Infections (metabolism)</term><term>HIV Infections (prevention & control)</term><term>HIV Infections (transmission)</term><term>Humans</term><term>Male</term><term>Sexually Transmitted Diseases (metabolism)</term><term>Sexually Transmitted Diseases (prevention & control)</term><term>Sexually Transmitted Diseases (transmission)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie rectale</term><term>Administration par voie vaginale</term><term>Animaux</term><term>Anti-infectieux (administration et posologie)</term><term>Anti-infectieux (métabolisme)</term><term>Essais cliniques comme sujet (tendances)</term><term>Femelle</term><term>Humains</term><term>Infections à VIH ()</term><term>Infections à VIH (métabolisme)</term><term>Infections à VIH (transmission)</term><term>Maladies sexuellement transmissibles ()</term><term>Maladies sexuellement transmissibles (métabolisme)</term><term>Maladies sexuellement transmissibles (transmission)</term><term>Mâle</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-infectieux</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>HIV Infections</term><term>Sexually Transmitted Diseases</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Anti-infectieux</term><term>Infections à VIH</term><term>Maladies sexuellement transmissibles</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term><term>Sexually Transmitted Diseases</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Essais cliniques comme sujet</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>HIV Infections</term><term>Sexually Transmitted Diseases</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Clinical Trials as Topic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intravaginal</term><term>Administration, Rectal</term><term>Animals</term><term>Female</term><term>Humans</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie rectale</term><term>Administration par voie vaginale</term><term>Animaux</term><term>Femelle</term><term>Humains</term><term>Infections à VIH</term><term>Maladies sexuellement transmissibles</term><term>Mâle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The impetus for, and efforts in the past 20 years toward a women-initiated method for preventing sexual transmission of HIV has been previously well described. To date, four classes of topical agents categorized by mechanism of action as: surfactants, buffers, cell entry blockers and antiretroviral agents have undergone advanced clinical testing. Thus far, only coitally linked use of 1% tenofovir gel has demonstrated moderate effectiveness in preventing HIV and HSV-2 infection and has generated renewed hope for microbicide development. Studies of new antiviral agents, novel delivery mechanisms and combination/multipurpose products that address challenges of adherence and enhance the effectiveness of tenofovir gel are already underway to further enhance sexual and reproductive health needs of men and women and efforts to prevent HIV infection.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li></country></list><tree><noCountry><name sortKey="Baxter, Cheryl" sort="Baxter, Cheryl" uniqKey="Baxter C" first="Cheryl" last="Baxter">Cheryl Baxter</name></noCountry><country name="Afrique du Sud"><noRegion><name sortKey="Karim, Quarraisha Abdool" sort="Karim, Quarraisha Abdool" uniqKey="Karim Q" first="Quarraisha Abdool" last="Karim">Quarraisha Abdool Karim</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002567 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002567 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23428099
|texte= Microbicides for the prevention of sexually transmitted HIV infection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23428099" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |